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Abstract
PCR assays have not reached the same level of acceptance for the detection of human fungal pathogens as for other micro-organisms, mainly
because the low number of micro-organisms challenges the detection limits of PCR. Therefore, whereas meta-analyses focusing on clinical
validation suggest interest in adding PCR results to the diagnostic workup for invasive fungal disease (IFD) along with clinical evaluation, CT
scans, classical mycology and antigen detection, no consensual PCR method has emerged. Compared with the end-point format of the
1990s, real-time quantitative PCR is a major breakthrough. This format prevents contamination with previously ampliﬁed products, provides
the yield of ampliﬁcation, allows for developing consensus procedures and should therefore be the only format used. An internal control is
now mandatory to avoid false-negative results. Primer design strongly impacts on the objectives: pan-fungal primers can provide
false-positive results due to environmental fungal DNA contamination; conversely, species-speciﬁc primers miss infections caused by
untargeted fungi. Unresolved issues include the best specimens to be used; serum is currently preferred to blood because of the ease of the
DNA extraction step. Work is in progress to establish standards at least for Aspergillus PCR, and the implementation of quality controls
should help centres to improve assays. Eventually, the classical analysis of biomarker performance does not consider the evolving risk
factors and changing treatments during IFD, which can lead to variable conclusions. New statistical methods such as event history analysis
should be considered.
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Introduction
Molecular diagnostic tests for invasive fungal diseases (IFD)
have a huge spectrum of applications, such as species identi-
ﬁcation and genotyping, which are not discussed here. The main
ﬁeld of investigation of clinical importance is the detection of
Candida and Aspergillus in human specimens. The aim is to
include molecular tests, mainly PCR assays, in the diagnostic
workup of diagnosing IFD, which remains a multidisciplinary
analysis of clinical and CT scan data, and microbiological
ﬁndings, including classical mycology and antigen detection [1].
In addition, PCR assays can be designed for the detection of
antifungal drug resistance, which is a growing concern [2].
The number of publications dealing with PCR assays aiming
at improving diagnosis and treatment management of IFD has
been increasingly expending in the past 20 years to overcome
the limits of other diagnostic methods in mycology [3,4].
Thus, it may seem strange that PCR results are still not
included in the consensus criteria for deﬁnitions of IFD [1],
despite numerous meta-analyses for Aspergillus [5–8] and
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Candida [9], showing that the sensitivity and speciﬁcity of
these PCR tests are at least as good as antigen detection.
Unfortunately, the PCR format is usually not considered as a
critical point in published meta-analyses. As a consequence,
no consensus had emerged regarding the implementation of
PCR tests in a routine laboratory. For instance, a PubMed
interrogation (January 1 2013) with “Aspergillus,” “PCR” and
“diagnosis” over the last ﬁve years provided 252 publications
and 24 reviews in English with numerous differences regard-
ing (i) DNA targets, (ii) probes (hydrolysis probes, hybrid-
ization probes or molecular beacons) and (iii) the
PCR equipment used. To reach a consensus on a given assay
is unrealistic in contrast to a consensus on PCR procedures.
The aim of this review was to describe some technical
limitations speciﬁc to invasive aspergillosis (IA) and candidi-
asis. The discussion of these limitations may also lead
clinicians to pay more attention to PCR tests and to be
more critical when assessing the conclusions of some studies.
PCR Format for Diagnosing IFD
The generally very low amount of fungal DNA in clinical
specimens challenges the limits of PCR assays. In focusing on
increasing sensitivity, the risk of false-positive results due to
contamination by either PCR amplicons or environmental
DNA increases as well. To prevent false-positives due to
amplicon contamination, uracil-N-glycosylase treatment has
been proposed for more than 20 years [10,11], but enzymatic
methods have been slowly implemented in PCR assays.
Currently, the best means to prevent amplicon contamination
are the closed format provided by real-time quantitative PCR
(qPCR) [12,13].
The qPCR format dramatically reduces the risk of carry-
over contamination by environmental amplicons and the
potential for false-positive results. By opening tubes between
two runs of ampliﬁcation, nested PCR negates the main
advantage of the closed-tube format. The technical perfor-
mance of a qPCR test should also be optimized following the
“Minimum Information for the publication of real-time Quan-
titative PCR Experiments” (MIQE) guidelines [14,15]. An
analysis of the literature shows that the analytical features of
qPCR tests should be improved, particularly in highly ranked
journals [16].
Monitoring the Yield of Ampliﬁcation
In addition to the risk of false-positive results, PCR presents a
risk of false-negative results often linked to PCR inhibitors. To
prevent false-negatives, the use of an internal control (IC) of the
ampliﬁcation has been recommended in recent years [10,17].
The aim of the IC is to be sure that the yield of the reaction in a
given clinical specimen is as established after experimental
validation of the PCR assay. Any DNA fragment exogenous to
the considered PCR assay can be used, which excludes human
DNA genes when dealing with human specimens. Indeed, the
quantity of human DNA is often huge compared with the target
and is also highly variable, giving no clue regarding the yield of the
PCR. With an appropriate IC, a slight decrease in PCR yield can
be detected and adequate measures can be implemented to
improve DNA extraction steps and to reject samples with
incorrect IC ampliﬁcation to avoid false-negative results.
Primer Selection
The risk of false-positives in diagnostic PCR has led to the
delineation of physical measures of prevention, well-known for
years although not always easy to maintain in a routine
laboratory (a unidirectional workﬂow environment with
physically separated laboratories for pre-, peri- and post-PCR
analysis, wearing a gown and gloves, the use of aerosol-resis-
tant tips and speciﬁc pipettes). However, these measures are
inefﬁcient against another source of environmental DNA, that
is, DNA from micro-organisms present in the environment.
For instance, false-positive results have been reported due to
fungal DNA in sampling tubes [18] and in IV drugs [19]. Regular
tests of reagents or any suspected products using negative
extraction controls should be as numerous as possible.
Nevertheless, these contaminations generally correspond to
low levels of fungal DNA (<10 DNA copies), and alternatively
positive and negative results may lead by chance, according to
Poisson’s law, to falsely validate a negative control.
To decrease the risk of detecting environmental fungal
DNA, one can design primers very speciﬁc for the main target,
for example Aspergillus fumigatus for IA. Fig. 1 shows the
results of using qPCR to detect other mould DNAs when
different primer sets are used. Penicillium DNA, for instance,
can be ampliﬁed as efﬁciently as or more efﬁciently than
A. fumigatus DNA. If for any reason Penicillium DNA is present
in the PCR tube, it can be preferentially ampliﬁed due to the
competitive nature of PCR, leading to false-negative results,
even in presence of A. fumigatus DNA. On the other hand,
when using very speciﬁc primers, one must accept not being
able to detect other fungi, which may be clinically relevant,
such as Fusarium spp. or mucormycetes [20]. Therefore, more
speciﬁc assays lower the risk of false-positives with environ-
mental DNA but, unfortunately, are more likely to miss
non-fumigatus infection.
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20 (Suppl. 6), 36–41
CMI Alanio and Bretagne Molecular diagnostics of fungal infections 37
With “pan-fungal” primers, the speciﬁcity of the amplicon
cannot be assessed unless speciﬁc probes are used [12,13].
The analysis of melting curves using SYBR Green dye is only
indicative as this method lacks the required speciﬁcity for
clinical diagnostic assays [21]. Another reason for not using
“pan-fungal” primers is the huge amount of human DNA in
human samples. A pan-fungal design harbours the risk of
hybridization with any eukaryotic DNA, such as non-targeted
fungi and human DNA. For instance, the ITS1 primer
(50-TCCGTAGGTAACCTGCGG-30) perfectly matches with
human DNA and is inefﬁcient for testing human samples,
whereas it is recommended for identiﬁcation using pure fungal
DNA [22].
Clinical Specimens – DNA Extraction
When designing a PCR assay, the starting specimen is
obviously the ﬁrst question, which hugely impacts the choice
of the DNA extraction step. The best DNA extraction
procedure depends on the specimen (whole blood, serum,
respiratory specimens or tissue biopsy). Ideally, the DNA
extraction procedure should be automated to decrease the
work load and to avoid cross-contamination between nega-
tive and positive samples handled and processed in parallel
[23].
For Candida and Aspergillus infections, whole blood has long
been investigated with the general assumption that a
PCR-positive result means invasive disease. However, one
must admit our ignorance of the origin of DNA detected in
blood samples, and there has been no deﬁnitive demonstration
that whole blood is better than serum for the diagnosis of both
IA [24,25] and candidiasis [26,27].
Positive blood cultures for Aspergillus are extremely rare
[3] and are not considered for the deﬁnition of IA [1]. This
rarity suggests that living fungal particles are not the source
of positive PCR results. If, nevertheless, this hypothesis is
retained, a stringent DNA extraction protocol should be
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FIG. 1. The speciﬁcity results of seven primer sets are shown by subtracting the quantitative cut-off (Cq) obtained from the Aspergillus fumigatus IP
2279.94 strain to the Cq obtained from the same DNA quantity of different moulds. The higher is the ΔCq, the more speciﬁc for A. fumigatus the
primer set (Set 1). In contrast, a negative value means a low speciﬁcity for A. fumigatus (Sets 5–7). A low speciﬁcity allows to amplify other species
potentially responsible for invasive diseases, but exposes to a high rate of false positivity due to mould DNA widely present in the environment.
Reference strains list: Aspergillus fumigatus (IP 2279.94), Aspergillus ﬂavus (ATCC 204304), Aspergillus brasiliensis (CBS 733.88), Emericella nidulans var.
nidulans (CBS 121.35), Aspergillus insuetus (CBS 107.25), Aspergillus versicolor (CNRMA/F5-26), Aspergillus terreus (CNRMA/F07-91), Penicillium
chrysogenum (CNRMA/F02-26), Penicillium purpurogenum (CNRMA/F08-52), Rhizopus oryzae (CBS 112.07) and Cladosporium cladosporoides (IP 1232).
Fungi were grown on Sabouraud agar medium, and DNA was extracted from 7-day-old culture conidia using the MagNa Pure Compact Nucleic Acid
Isolation Kit in a MagNa Pure Compact apparatus (Roche Diagnostics, Meylan, France) according to the manufacturer’s instructions. DNA
concentration was determined using a spectrophotometer (Nanodrop ND-1000;Thermo Scientiﬁc, Wilmington, DE, USA). PCR reactions were
carried out in duplicates in a 20 lL ﬁnal volume containing 19 LightCycler 480 SYBR Green I Master (Roche Diagnostics), 500 nM of each primer
(Set1 [11], Set2 [18], Set3 [19], Set4 [16], Set5 [15], Set 6 [17], and Set7 [14]) and 5 ng of each fungal DNA species on a LightCycler 480 instrument
(Roche Diagnostics) with an initial denaturation step at 95°C for 8 min followed by 50 cycles at 95°C for 10 s, 60°C for 10 s and 72°C for 15 s.
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followed to free DNA from fungal elements, as suggested by
the European Aspergillus PCR Initiative (EAPCRI) [28]. The
rarity of positive blood cultures for IA has led to initial
work on serum [23,29]. If the hypothesis of cell-free fungal
DNA in serum is accepted, the DNA extraction procedure
is simpler, less damaging to DNA integrity and easily
amenable to automation [23,30]. The absence of a patho-
gen-speciﬁc DNA enrichment procedure indirectly favours
the hypothesis of circulating cell-free fungal DNA as the
source of the ampliﬁed DNA [31]. Additionally, empirical
comparisons currently favour serum for primary samples,
mainly because DNA extraction from serum is easier and
faster than from whole blood [24,25] and a larger volume
can be easily used [32,33]. Plasma might also be investigated,
although previous experimental data do not favour plasma
over serum [34].
For Candida DNA detection in blood, several authors have
reported results consistent with the circulation of nonviable
fungal components using the commercial kit SeptiFast [26,27].
A formal comparison between whole blood and serum showed
that Candida DNA was detected more often in serum (71%)
and plasma (75%) than in whole blood (54%) [35]. As for IA,
these observations impact the DNA extraction step. This also
questions the meaning of PCR-positive results as detecting
circulating yeast DNA may not have the same meaning as
detecting living yeasts.
PCRon respiratory specimens [bronchoalveolar lavage (BAL)
ﬂuid and sputum]was ﬁrst investigated to overcome the limits of
mould cultures [10]. As DNA in respiratory specimens comes
from spores or hyphae, to free DNA for ampliﬁcation neces-
sitates stringent DNA extraction procedures. Indeed, when
enzymatic digestion is used alone, the Aspergillus PCR sensitivity
is 70%, whereas the sensitivity increases to 94% when
bead-beating is used [8]. The other issue with respiratory
specimens is interpretation. The meaning of a PCR-positive
result can be true infection, colonization or bystander recovery,
because Aspergillus DNA can be detected in healthy individuals
[2]. To aid in interpretation, deﬁning thresholds could be
relevant, as for Pneumocystis pneumonia [36,37]. However, in
contrast to Pneumocystis jirovecii, which is equally spread in the
alveoli, Aspergillus is most often localized in speciﬁc foci.
Therefore, the detection or not of Aspergillus DNA hugely
depends on the quality of the BAL, which prevents the
establishment of consensus thresholds between hospitals.
Biopsies are also of obvious interest for IFD diagnosis [38].
For DNA investigations, the difﬁculties in extracting and
correctly amplifying DNA when biopsies are ﬁxed in formalin
must be underlined [39]. New sequencing methods seem
promising for the rapid identiﬁcation of hyphae in fresh
biopsies [40].
Evaluation of qPCR Assay Performance –
Clinical Evaluation
Once a reliable assay is available, the challenge is to include it in
a diagnostic strategy that is framed by clinical ﬁndings. The
PCR results must be integrated in a clinical workup, including
other validated markers such as antigen detection [41] as well
as direct examination and culture of samples. This workup is a
dynamic process where evolving risk factors and treatments
have a huge impact on biomarker value [42]. For instance, the
galactomannan test yield evolves with the duration of neutro-
penia, such that longer periods of neutropenia are associated
with a higher probability of a positive test. Therefore, to
consider an IFD episode as an entity without distinguishing, the
moment at which the test is positive can overestimate its
importance. Indeed, a positive test before or after the initiation
of antifungal drugs has not the same clinical value. This is why
we propose another method for clinical evaluation (Fig. 2),
that is, event history analysis [32]. We have conﬁrmed that the
risk of IA is a complex time function of neutropenia duration
and risk management. For patients with acute myeloid
leukaemia, a qPCR assay accelerated the early detection of
IA (p 0.01), independently of other diagnostic information
used for treatment, while the 1,3-beta-D-gluca assay did not
(p 0.53) [32]. The 1,3-beta-D-gluca assay is already included in
the diagnostic criteria for IFD while PCR is not [1].
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FIG. 2. Multi-State Model of Invasive Aspergillosis and Antifungal
Therapy in febrile, neutropenic patients with acute myeloid leukaemia.
Patients in the initial state free of antifungal therapy could (a1) develop
invasive aspergillosis (i.e. “baseline” invasive aspergillosis); (b1) get
treated; or (c1) remain untreated. Once antifungal therapy was started,
patients could (a2) develop invasive aspergillosis despite treatment (i.e.
“breakthrough” invasive aspergillosis); (b2) be removed from treat-
ment; or (c2) remain treated.
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The next step is the integration of PCR results into patient
management. Hebart et al. [43] did not ﬁnd any difference at
day 100 in the incidence of IFD (primary end-point) and
survival between PCR-based and empirical treatment with
liposomal amphotericin B in patients after allogeneic stem cell
transplantation. Blennow et al. [44] concluded that Aspergillus
PCR tests on peripheral blood are a poor indicator of IFD
early after allogeneic graft and are therefore insufﬁciently
sensitive to be diagnostically useful. When looking at the risk
of withholding empiric antifungal treatment in PCR-negative
patients, Barnes et al. [45] did not ﬁnd any excess morbidity or
mortality, whereas there were substantial savings in antifungal
drug expenditure. Similarly, Morrissey et al. [46] found that
galactomannan and nested PCR reduced the use of empirical
antifungal treatment. Given the huge diversity between the
PCR tests used in these studies, it is currently impossible to
draw any ﬁrm conclusions on the importance of treating a
given patient based on a positive PCR result.
Conclusion – Perspectives
Work is in progress to establish standards for Aspergillus PCR
for whole blood [28] and for serum [30]. Centres that follow
the protocol of the European Aspergillus PCR initiative (a
working group of the International Society for Human and
Animal Mycology) obtain better results than those that do not
[47]. MIQE validation, internal controls and automated DNA
extraction are being used more often, and this should increase
the reliability of the PCR assays. Participation in external
quality control programmes is also becoming compulsory for
hospital laboratories, allowing participating teams to improve
their own tests.
There are still critical unresolved issues on the origin of the
DNA detected in clinical samples, leaving room for studies
providing a rationale for modifying the choice of the best
clinical specimen and the best DNA extraction procedure.
Primer choice is still controversial, that is, species-speciﬁc vs.
pan-fungal, with pros and cons for each choice. Clinical
validation should take into consideration the complex time
function of risk factors of IFDs and their management. It is also
necessary to determine whether next-generation sequencing
strategies will change the way we develop and perform
molecular tests on patients.
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